A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors.

Jian Li, Lin Shen, Yi Huang et al.|Journal of Clinical Oncology|2021

Cited by 15